NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $2.14 -0.04 (-1.83%) Closing price 05/2/2025 03:41 PM EasternExtended Trading$2.14 0.00 (0.00%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CollPlant Biotechnologies Stock (NASDAQ:CLGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CLGN alerts:Sign Up Key Stats Today's Range$2.15▼$2.2450-Day Range$2.00▼$3.5152-Week Range$2.00▼$6.75Volume4,929 shsAverage Volume11,281 shsMarket Capitalization$24.51 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company OverviewCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Read More… CollPlant Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCLGN MarketRank™: CollPlant Biotechnologies scored higher than 42% of companies evaluated by MarketBeat, and ranked 439th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingCollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.03% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.03% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentCollPlant Biotechnologies has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address CLGN Stock News HeadlinesCollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety StudiesApril 15, 2025 | prnewswire.comCollPlant provides corporate updateMarch 27, 2025 | markets.businessinsider.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 3, 2025 | Brownstone Research (Ad)CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | insidermonkey.comCollPlant Biotechnologies Reports 2024 Financial ResultsMarch 27, 2025 | tipranks.comCollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | seekingalpha.comCollPlant’s Earnings Call: Mixed Outlook Amid InnovationsMarch 26, 2025 | tipranks.comCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATEMarch 26, 2025 | prnewswire.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $3.60 at the beginning of 2025. Since then, CLGN stock has decreased by 40.6% and is now trading at $2.14. View the best growth stocks for 2025 here. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) issued its quarterly earnings data on Wednesday, March, 26th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.36 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 77.05% and a negative net margin of 2,680.00%. Read the conference call transcript. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' top institutional shareholders include Brown Advisory Inc. (0.97%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA). Company Calendar Last Earnings3/26/2025Today5/03/2025Next Earnings (Estimated)5/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLGN CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$14.00 Low Stock Price Target$11.00 Potential Upside/Downside+484.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net Margins-2,680.00% Pretax Margin-2,680.00% Return on Equity-77.05% Return on Assets-61.43% Debt Debt-to-Equity RatioN/A Current Ratio5.38 Quick Ratio5.23 Sales & Book Value Annual Sales$515,000.00 Price / Sales47.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book0.87Miscellaneous Outstanding Shares11,455,000Free Float10,355,000Market Cap$24.51 million OptionableOptionable Beta1.24 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:CLGN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.